Repurposing FDA-Approved Drugs as Fructosamine-3-Kinase Inhibitors: A Mechanistic and Translational Approach to Redox-Driven Cancer Therapy
{{output}}
Fructosamine-3-kinase (FN3K), a deglycating enzyme originally studied in the context of diabetes, has recently emerged as a pivotal modulator of redox homeostasis and therapeutic resistance in cancer. FN3K catalyzes the removal of early glycation adducts, ther... ...
